甲磺酸阿帕替尼联合化疗治疗晚期胃癌的效果及安全性  

Efficacy and safety of apatinib mesylate combined with chemotherapy in treatment of advanced gastric cancer

作　　者：陈郭勇 夏冬 CHEN Guo-yong;XIA Dong(Department of Gastrointestinal Surgery,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,China)

机构地区：[1]西南医科大学附属医院胃肠外科,四川泸州646000

出　　处：《中国药物应用与监测》2023年第5期360-363,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的:探究甲磺酸阿帕替尼联合OXA+5-Fu/CF治疗晚期胃癌的效果及安全性。方法:纳入130例晚期胃癌患者。以随机数字表法分成两组,脱落9例,合计121例;单纯化疗组60例,采取OXA+5-Fu/CF化疗;结合用药组61例,采取甲磺酸阿帕替尼联合OXA+5-Fu/CF化疗,比较两组疗效指标。结果:结合用药组总有效率(68.85%)比单纯化疗组(50.00%)高,差异具有统计学意义(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05);结合用药组无进展生存时间、生存时间分别为(2.44±0.34)年、(3.99±0.56)年,均长于单纯化疗组[(2.00±0.27)年、(2.89±0.50)年],差异具有统计学意义(P<0.05);结合用药组治疗后神经元特异性烯醇化酶(neuron-specific enolase,NSE)、血清糖类抗原19-9(carbohydrateantigen 19-9,CA19-9)、癌胚抗原(carcinoembryonic antigen,CEA)与糖类抗原125(carbohydrate antigen 125,CA125)水平分别为(25.39±3.31)U·mL^(-1)、(6.40±1.85)ng·mL^(-1)、(30.26±3.19)U·mL^(-1)、(22.10±4.83)g·L^(-1),均下降低于单纯化疗组[(34.23±4.91)U·mL^(-1)、(10.64±1.63)ng·mL^(-1)、(38.64±4.12)U·mL^(-1)、(30.26±4.82)g·L^(-1)],差异具有统计学意义(P<0.05)。结论:晚期胃癌采取OXA+5-Fu/CF化疗与甲磺酸阿帕替尼治疗效果良好,安全可靠。Objective:To explore the efficacy and safety of apatinib mesylate combined with OXA+5-Fu/CF in the treatment of advanced gastric cancer.Methods:A total of 130 cases of advanced gastric cancer were included and randomized into two groups.Of the 130 cases,9 fell off and the other 121 completed the whole-course treatment.The patients in the single chemotherapy group(60 in number)were treated with OXA+5-Fu/CF chemotherapy,and those in the combined drug group(61 in number)with Apatinib mesylate combined with OXA+5-Fu/CF chemotherapy,and indicators were compared between the 2 groups.Results:The total effective rate was signifcantly higher in the combined treatment group(68.85%)than in the chemotherapy group(50.00%)(P<0.05).The occurring rate of adverse reactions was of no statistical difference between the 2 groups(P>0.05).The progression-free survival time and survival time in the combined treatment group were(2.44±0.34)years and(3.99±0.56)years,respectively,which were longer than those of(2.00±0.27)years and(2.89±0.50)years in the chemotherapy group(P<0.05).The levels of neuron-specific enolase(NSE),serum carbohydrateantigen 19-9(CA19-9),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)were significantly lower in the combined treatment group((25.39±3.31)u·mL^(-1),(6.40±1.85)ng·mL^(-1),(30.26±3.19)u·mL^(-1),(22.10±4.83)g·L^(-1))than in the single chemotherapy group((34.23±4.91)u·mL^(-1),(10.64±1.63)ng·mL^(-1),(38.64±4.12)u·mL^(-1),(30.26±4.82)g·L^(-1))(P<0.05).Conclusion:OXA+5-Fu/CF chemotherapy and apatinib mesylate are effective and safe in the treatment of advanced gastric cancer.

关 键 词：晚期胃癌 甲磺酸阿帕替尼 OXA+5-Fu/CF化疗方案 疗效 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]